With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based ...

Following an extensive Middle East military build-up by the U.S. in recent weeks, the U.S. and Israel on Feb. 28 launched ...

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...

Ahead of a rescheduled meeting of the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis (PrEP) medicine, Gilead Sciences is tapping ...

Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs that it says are often overlooked by bigger ...

Since the start of the millennium, podcasts have gone from nonexistent to numbering in the millions, and Edison Research ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

The nod allows Hernexeos (zongertinib) to be used as an initial treatment option for NSCLC with HER2-activating mutations in ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...